These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 29329976

  • 1. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D, Lv G.
    Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
    [Abstract] [Full Text] [Related]

  • 2. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH, Jeon SJ, Cho KS, Moon E, Sapkota A, Jun HS, Ryu JH, Choi JW.
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [Abstract] [Full Text] [Related]

  • 3. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [Abstract] [Full Text] [Related]

  • 4. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A, Goyal A.
    Eur J Pharmacol; 2024 Nov 05; 982():176936. PubMed ID: 39182542
    [Abstract] [Full Text] [Related]

  • 5. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 6. Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury.
    Han W, Li Y, Cheng J, Zhang J, Chen D, Fang M, Xiang G, Wu Y, Zhang H, Xu K, Wang H, Xie L, Xiao J.
    J Cell Mol Med; 2020 Aug 01; 24(15):8687-8702. PubMed ID: 32573108
    [Abstract] [Full Text] [Related]

  • 7. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 8. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases.
    Zhang L, Zhang W, Tian X.
    Int J Neurosci; 2023 May 01; 133(5):473-491. PubMed ID: 33941038
    [Abstract] [Full Text] [Related]

  • 9. Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice.
    Ruska Y, Csibi A, Dorogházi B, Szilvásy-Szabó A, Mohácsik P, Környei Z, Dénes Á, Kádár A, Puskár Z, Hrabovszky E, Gereben B, Wittmann G, Fekete C.
    Sci Rep; 2024 Jun 22; 14(1):14403. PubMed ID: 38909126
    [Abstract] [Full Text] [Related]

  • 10. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R, Almutairi M, Ussher JR.
    Peptides; 2018 Feb 22; 100():94-100. PubMed ID: 29412838
    [Abstract] [Full Text] [Related]

  • 11. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D, Foltynie T.
    Drug Discov Today; 2016 May 22; 21(5):802-18. PubMed ID: 26851597
    [Abstract] [Full Text] [Related]

  • 12. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.
    Li L.
    CNS Drugs; 2017 Jul 22; 31(7):535-549. PubMed ID: 28540646
    [Abstract] [Full Text] [Related]

  • 13. Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior.
    Harasta AE, Power JM, von Jonquieres G, Karl T, Drucker DJ, Housley GD, Schneider M, Klugmann M.
    Neuropsychopharmacology; 2015 Jul 22; 40(8):1969-78. PubMed ID: 25669605
    [Abstract] [Full Text] [Related]

  • 14. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, Arroba AI, Valverde AM, Simó R.
    Diabetes; 2016 Jan 22; 65(1):172-87. PubMed ID: 26384381
    [Abstract] [Full Text] [Related]

  • 15. Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.
    Yang L, Yao D, Yang H, Wei Y, Peng Y, Ding Y, Shu L.
    Mol Endocrinol; 2016 Mar 22; 30(3):361-71. PubMed ID: 26789107
    [Abstract] [Full Text] [Related]

  • 16. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
    Perry T, Greig NH.
    Curr Alzheimer Res; 2005 Jul 22; 2(3):377-85. PubMed ID: 15974903
    [Abstract] [Full Text] [Related]

  • 17. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug 22; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 19. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 29; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.
    CNS Drugs; 2019 Mar 29; 33(3):209-223. PubMed ID: 30511349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.